Liquid biopsy tests provide access to tumor DNA in a minimally invasive way, offering great potential in oncology applications, including precision medicine, early cancer diagnosis and disease’s follow-up and monitoring.
At Aniling, we have developed a new product, GEUS-LB, targeting liquid biopsy in colorectal cancer patients. Our GEUS technology consists of proprietary reagents and software and gets the most from liquid biopsy samples by integrating, for the first time, genetics and epigenetics tests into a single one.
We are currently validating GEUS-LB in a cohort of colorectal cancer patients in collaboration with two leading health institutions, Catalan Institute of Oncology (ICO) and Germans Trias i Pujol Research Institute (IGTP), and the support of the Spanish Ministry of Science and Innovation.